Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Mavoglurant in Adult Fragile X Syndrome
NCT01348087Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of mavoglurant in Fragile X syndrome (FXS), sponsored by Novartis. Primary endpoint: Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Aug 2011; status: terminated.
02
Drugs
mavoglurant
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01348087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01348087.